Literature DB >> 34339769

Genetic factors may affect the severity of COVID-19.

Zhenzhen Zheng1, Yuanming Zhou2, Xishi Sun3, Zhiqiang Wang4, Chaoyu Wang5, Jiangpeng Lin6, Ziyi Wang7, Yanhong Liu5, Xiaojuan Chen4, Nanhong Li8, Yu Zeng9, Riken Chen10.   

Abstract

Entities:  

Year:  2021        PMID: 34339769      PMCID: PMC8323502          DOI: 10.1016/j.ijcard.2021.07.058

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


× No keyword cloud information.
To the Editor: We have read with great interest of the article by Minhas et al. [1], in which indicates adjusted odds of myocardial injury, ischemic stroke and all-cause mortality are significantly higher in men compared to women with COVID-19.Higher inflammatory markers are present in men but associated similarly with risk in both men and women, suggesting that adverse cardiovascular outcomes in men vs. women are independent of cardiovascular comorbidities. This finding is important, previous studies suggest men have consistently higher mortality from COVID-19 compared to women and this sex difference in mortality may be related to greater underlying comorbidities in men, such as cardiovascular disease (CVD), which have been linked to increased severity of COVID-19 [2,3]. Therefore, these cannot explain the various changes in the severity of the illness. There is also a genetic factor that cannot be ignored. Based on the difference in severity, researchers found 4 sites related to the susceptibility and 9 sites related to the severity of COVID-19.The identified chromosomal loci include some genes that have been found to be associated with autoimmune diseases, inflammatory diseases, or lung diseases in past studies. For example, a variant of DPP9 will increase the risk of severe COVID-19, while the same variant will also increase the risk of lung disease characterized by scarring of lung tissue. Another genomic mutation in the OAS gene causes a decrease in the OAS1 enzyme in the blood. OAS1 can digest viral RNA, and a decrease in OAS1 increases the risk of infection, hospitalization, and critical illness [4]. Currently, pharmaceutical company is conducting research and development work on OAS [5].

Funding sources

The work was supported by the Science and Technology Planning Project of Panyu District, Guangzhou (No.2020-Z04-102).

Author contributors

All authors contributed to the writing, review and approval of the final copy of the manuscript.

Declaration of Competing Interest

None declared.
  5 in total

1.  The quest to find genes that drive severe COVID.

Authors:  Ewen Callaway
Journal:  Nature       Date:  2021-07       Impact factor: 49.962

2.  The role of sex and inflammation in cardiovascular outcomes and mortality in COVID-19.

Authors:  Anum S Minhas; Julie K Shade; Sung-Min Cho; Erin D Michos; Thomas Metkus; Nisha A Gilotra; Garima Sharma; Natalia Trayanova; Allison G Hays
Journal:  Int J Cardiol       Date:  2021-05-08       Impact factor: 4.164

3.  Mapping the human genetic architecture of COVID-19.

Authors: 
Journal:  Nature       Date:  2021-07-08       Impact factor: 69.504

4.  Sex Differences in Mortality Rates and Underlying Conditions for COVID-19 Deaths in England and Wales.

Authors:  Mohamed O Mohamed; Chris P Gale; Evangelos Kontopantelis; Tim Doran; Mark de Belder; Miqdad Asaria; Thomas Luscher; Jianhua Wu; Muhammad Rashid; Courtney Stephenson; Tom Denwood; Chris Roebuck; John Deanfield; Mamas A Mamas
Journal:  Mayo Clin Proc       Date:  2020-07-23       Impact factor: 7.616

5.  Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19).

Authors:  Tao Guo; Yongzhen Fan; Ming Chen; Xiaoyan Wu; Lin Zhang; Tao He; Hairong Wang; Jing Wan; Xinghuan Wang; Zhibing Lu
Journal:  JAMA Cardiol       Date:  2020-07-01       Impact factor: 14.676

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.